Brief communication: Effect of chlorambucil on thymidine utilization by Yoshida ascites tumor cells.

B. Hill,M. Tattersall

Journal of the National Cancer Institute

Abstract:

What problem does this paper attempt to address?

Single-cell RNA Sequencing Reveals the Dynamics of Hepatic Non-Parenchymal Cells in Autoprotection Against Acetaminophen-Induced Hepatotoxicity

Lingqi Yu,Jun Yan,Yingqi Zhan,Anyao Li,Lidan Zhu,Jingyang Qian,Fanfan Zhou,Xiaoyan Lu,Xiaohui Fan

DOI: https://doi.org/10.1016/j.jpha.2023.05.004

IF: 14.026

2023-01-01

Journal of Pharmaceutical Analysis

Abstract:Gaining a better understanding of autoprotection against drug-induced liver injury (DILI) may provide new strategies for its prevention and therapy. However, little is known about the underlying mechanisms of this phenomenon. We used single-cell RNA sequencing to characterize the dynamics and functions of hepatic non-parenchymal cells (NPCs) in autoprotection against DILI, using acetaminophen (APAP) as a model drug. Autoprotection was modeled through pretreatment with a mildly hepatotoxic dose of APAP in mice, followed by a higher dose in a secondary challenge. NPC subsets and dynamic changes were identified in the APAP (hepatotoxicity-sensitive) and APAP-resistant (hepatotoxicity-resistant) groups. A chemokine (C-C motif) ligand 2 thorn endothelial cell subset almost disappeared in the APAP-resistant group, and an R-spondin 3 thorn endothelial cell subset promoted hepatocyte proliferation and played an important role in APAP autoprotection. Moreover, the dendritic cell subset DC-3 may protect the liver from APAP hepatotoxicity by inducing low reactivity and suppressing the autoimmune response and occurrence of inflammation. DC-3 cells also promoted angiogenesis through crosstalk with endothelial cells via vascular endothelial growth factor-associated ligand-receptor pairs and facilitated liver tissue repair in the APAP-resistant group. In addition, the natural killer cell subsets NK-3 and NK-4 and the Sca-1 -CD62L thorn natural killer T cell subset may promote autoprotection through interferon-g-dependent pathways. Furthermore, macrophage and neutrophil subpopulations with anti-inflammatory phenotypes promoted tolerance to APAP hepatotoxicity. Overall, this study reveals the dynamics of NPCs in the resistance to APAP hepatotoxicity and provides novel insights into the mechanism of autoprotection against DILI at a high resolution. & COPY; 2023 The Author(s). Published by Elsevier B.V. on behalf of Xi'an Jiaotong University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Epigallocatechin-3-gallate Mo nanoparticles (EGM NPs) efficiently treat liver injury by strongly reducing oxidative stress, inflammation and endoplasmic reticulum stress

Yunrong Yang,Min Liu,Tianjiao Zhao,Qiaohui Chen,Yuqi Yang,Shuya Wang,Jinping Zhang,Guiming Deng,Kewei Sun,Yayun Nan,Ke Cao,Kelong Ai,Qiong Huang

DOI: https://doi.org/10.3389/fphar.2022.1039558

IF: 5.6

2022-10-08

Frontiers in Pharmacology

Abstract:Drug-induced liver injury (DILI) is a serious clinical disease associated with reactive oxygen species (ROS) burst and subsequent inflammatory responses. However, traditional treatments were limited by low efficacy and serious side effects due to the special liver structure. Here, we developed a molybdenum (Mo)-based nanoparticles, EGM NPs, after overall consideration of the pathophysiology of DILI and the advantages of nanodrugs. It demonstrated that EGM NPs treated acetaminophen (APAP)-induced DILI by scavenging ROS and inhibiting inflammation. EGM NPs effectively scavenged various ROS and reduced cell apoptosis at the cellular level. More importantly, EGM NPs can treat APAP-induced DILI in vivo , reducing the levels of liver function indicators in mice with liver injury, scaling down the area of hepatocyte necrosis and successfully inhibiting endoplasmic reticulum (ER) stress in the liver. EGM NPs also showed a certain anti-inflammatory effect by reducing infiltration of macrophages, decreasing pro-inflammatory factors and inhibiting the expression levels of inducible nitric oxide synthase (NOS2) and myeloperoxidase (MPO). Collectively, our findings suggest that EGM NPs-based nanotherapeutic is a novel strategy for the treatment of DILI.

pharmacology & pharmacy
Multienzyme Active Manganese Oxide Alleviates Acute Liver Injury by Mimicking Redox Regulatory System and Inhibiting Ferroptosis

Aimin Wu,Min Li,Yinyin Chen,Wei Zhang,Haoran Li,Junzhou Chen,Ke Gu,Xianxiang Wang

DOI: https://doi.org/10.1002/adhm.202302556

Abstract:Drug-induced liver injury (DILI) is a severe condition characterized by impaired liver function and the excessive activation of ferroptosis. Unfortunately, there are limited options currently available for preventing or treating DILI. In this study, MnO2 nanoflowers (MnO2Nfs) with remarkable capabilities of mimicking essential antioxidant enzymes, including catalase, superoxide dismutase (SOD), and glutathione peroxidase are successfully synthesized, and SOD is the dominant enzyme among them by density functional theory. Notably, MnO2Nfs demonstrate high efficiency in effectively eliminating diverse reactive oxygen species (ROS) such as hydrogen peroxide (H2O2), superoxide anion (O2 •-), and hydroxyl radical (•OH). Through in vitro experiments, it is demonstrated that MnO2Nfs significantly enhance the recovery of intracellular glutathione content, acting as a potent inhibitor of ferroptosis even in the presence of ferroptosis activators. Moreover, MnO2Nfs exhibit excellent liver accumulation properties, providing robust protection against oxidative damage. Specifically, they attenuate acetaminophen-induced ferroptosis by inhibiting ferritinophagy and activating the P62-NRF2-GPX4 antioxidation signaling pathways. These findings highlight the remarkable ROS scavenging ability of MnO2Nfs and hold great promise as an innovative and potential clinical therapy for DILI and other ROS-related liver diseases.
Preclinical Validation of Silibinin/albumin Nanoparticles As an Applicable System Against Acute Liver Injury.

Yuan Ding,Sitong Zhang,Zhongquan Sun,Zongrui Tong,Yao Ge,Liuzhi Zhou,Qianhui Xu,Huiping Zhou,Weilin Wang

DOI: https://doi.org/10.1016/j.actbio.2022.04.021

IF: 10.633

2022-01-01

Acta Biomaterialia

Abstract:Background: Silibinin (SIL) has been extensively studied for its therapeutic effects on various liver diseases. However, its effect on acute liver injury was limited for poor solubility and low bioavailability. Thus, we prepared SIL and bovine serum albumin (SIL/BSA) nanoparticles and further evaluated their therapeutic efficacy against acute liver injury in mouse models.Methods: SIL/BSA nanoparticles were prepared via a nanoprecipitation method. Both in vitro cell culture model and in vivo mouse models of acetaminophen (APAP) and lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury were used to evaluate the therapeutic effect of SIL/BSA nanoparticles and potential mechanisms. Results: The SIL/BSA nanoparticles with hydrophilic diameters of 90 +/- 29 nm were stably suspended. SIL/BSA nanoparticles presented better biocompatibility and more liver distribution in vivo than SIL microparticles. SIL/BSA nanoparticles significantly alleviated APAP and LPS/D-GalN induced acute liver injury in mice. Similarly, SIL/BSA nanoparticles remarkably enhanced the viability of hepatocytes in vitro against both APAP and LPS/D-GalN induced hepatocyte damage. Moreover, SIL/BSA nanoparticles exhibited antioxidant effects against intracellular oxidative stress via upregulating the nuclear factor erythroid 2-related factor 2 (Nrf2)/antioxidant responsive element (ARE) pathway, decreasing ROS and regulating antioxidant enzyme reactivity. And the downstream of mitochondria damage and caspase 9/3 related apoptosis pathway was also inhibitedConclusion: SIL/BSA nanoparticles were successfully prepared to enhance the liver availability of SIL. Both in vivo and in vitro , SIL/BSA nanoparticles exerted ideal hepatoprotective and antioxidant efficacy against acute liver injury, suggesting the promising future in clinical transfer.
Alteration of Bile Acids and Omega-6 PUFAs Are Correlated With the Progression and Prognosis of Drug-Induced Liver Injury

Shuang Zhao,Haoshuang Fu,Tianhui Zhou,Minghao Cai,Yan Huang,Qinyi Gan,Chenxi Zhang,Cong Qian,Jiexiao Wang,Zhenglan Zhang,Xiaolin Wang,Xiaogang Xiang,Qing Xie

DOI: https://doi.org/10.3389/fimmu.2022.772368

IF: 7.3

2022-04-12

Frontiers in Immunology

Abstract:Background & Aims Drug-induced liver injury (DILI) is one of the leading causes of liver failure with some of the patients progressed to chronic DILI. The mechanisms underlying the severity and chronicity of DILI are poorly elucidated and the biomarkers are limited. Metabolites and gut microbiota played a crucial role in the development of various liver diseases. Herein, a systematic analysis of serum metabolites and gut microbiota was performed in DILI patients, aiming to identify metabolites correlated with the progression and clinical prognosis of DILI. Methods Various serum metabolites were quantitated using a metabolite array technology in this prospective study. Gut microbiome compositions and the expression profiles of liver genes were determined in patients with DILI and healthy controls. Results Metabolomic analysis revealed that bile acids (BAs) and polyunsaturated fatty acids (PUFAs) were closely related to DILI severity and chronicity respectively. The ratios of serum primary/secondary BAs and omega-6/omega-3 PUFAs were elevated in DILI patients. A model established by adrenic acid (AdA) and aspartic acid (Asp) exerts good performance for predicting the chronicity of DLIL. Hepatic transcriptome revealed enhanced expression of PUFA peroxidation and supressed expression of BA synthesis related genes in DILI patients. In addition, Lactic acid bacteria and BA converting bacteria were increased in gut of DILI patients. Besides, elevated serum malondialdehyde (MDA) and fibroblast growth factor 19 (FGF19) was observed in DILI patients. Conclusion BAs and PUFAs could be potent markers for the severity and chronicity of DILI respectively. The panel of AdA and Asp could be ideal predictive model for the risk of chronicity at the acute stage of DILI. Gut microbiota might act as a negative feedback mechanism to maintain the homeostasis of BAs and PUFAs via FGF19 signalling and PUFA saturation, respectively. Our study revealed novel biomarkers for severe and chronic DILI and provided new therapeutic targets for DILI.

immunology
Bifidobacterium Longum R0175 Protects Mice Against APAP-induced Liver Injury by Modulating the Nrf2 Pathway.

Shengjie Li,Aoxiang Zhuge,Jiafeng Xia,Shuting Wang,Longxian Lv,Kaicen Wang,Huiyong Jiang,Ren Yan,Liya Yang,Xiaoyuan Bian,Xianwan Jiang,Qiangqiang Wang,Shengyi Han,Lanjuan Li

DOI: https://doi.org/10.1016/j.freeradbiomed.2023.03.026

2023-01-01

Abstract:Acetaminophen (APAP) overdose is the most common driver of drug-induced liver injury (DILI) worldwide, and the gut microbiome plays a crucial role in this process. In this study, we estimated the effect of Bifidobacterium longum R0175 on APAP-induced liver injury in mice and discovered that B. longum R0175 alleviated liver injury by diminishing inflammation, reducing oxidative stress levels, inhibiting hepatocyte death and improving APAP-induced microbiome dysbiosis. Further studies revealed that the antioxidative effects of B. longum R0175 were primarily due to activation of the Nrf2 pathway, which was supported by the Nrf2 pathway inhibitor ML385 counteracting these ameliorative effects. B. longum R0175 modified intestinal metabolites, especially the key metabolite sedanolide, which could activate the Nrf2 pathway and contribute to the protective effects against APAP-induced liver injury. Moreover, we found that sedanolide exhibited close interrelationships with specific microbial taxa, indicating that this factor may be derived from gut microbes. In conclusion, our work demonstrated that B. longum R0175 could reduce oxidative damage, inflammation and hepatocyte death by activating the Nrf2 pathway. Importantly, we identified the microbiota-derived metabolite sedanolide, which was first discovered in the mouse intestine, as a key agonist of the Nrf2 pathway and primary effector of B. longum R0175 in APAP challenge. These findings provide new perspectives for APAP overdose therapy and demonstrate the enormous potential of B. longum R0175 in alleviating acute liver injury.
Dual detoxification and inflammatory regulation by ceria nanozymes for drug-induced liver injury therapy

Fangyuan Li,Yueping Qiu,Fan Xia,Heng Sun,Hongwei Liao,An Xie,Jiyoung Lee,Peihua Lin,Min Wei,Yanfei Shao,Bo Yang,Qinjie Weng,Daishun Ling

DOI: https://doi.org/10.1016/j.nantod.2020.100925

IF: 17.4

2020-12-01

Nano Today

Abstract:Drug-induced liver injury (DILI) is the predominant cause of acute liver failure in many countries, which is closely associated with reactive oxygen species (ROS) and inflammation. Although N-acetylcysteine (NAC) is presently the first-choice antidote for DILI, it often fails to benefit the late stage patients due to its narrow therapeutic time window. Herein, we report ceria nanozymes (CeNZs) that simultaneously scavenge reactive oxygen species and generate oxygen for the treatment of acetaminophen-induced liver injury (a typical form of DILI), enabling a prolonged therapeutic time window as compared to NAC. It is found that CeNZs can effectively scavenge ROS in impaired hepatocytes for detoxification. More importantly, CeNZs can generate abundant oxygen based on their catalase (CAT)-mimic activity, thus further alleviating hypoxia and specifically inhibiting the pro-inflammatory macrophages to relieve inflammation for a promoted hepatocyte regeneration of DILI, which is vital for the treatment of late stage DILI when there is already massive hepatocyte necrosis. The dual detoxification and inflammatory regulation by CeNZs for DILI treatment with relatively long therapeutic time window as compared to NAC, together with the revealed mechanism herein, suggesting the future clinical use of CeNZs for DILI treatment, especially for the late stage DILI treatment.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
Network meta-analysis of different liver protective drugs in the treatment of drug-induced liver injury

Chengcheng Li,Xin Yang,Yuhang Quan,Anhao Wu,Yifan Wang

DOI: https://doi.org/10.1097/MD.0000000000036538

2023-12-15

Abstract:Background: Currently, drug-induced liver injury (DILI) has become one of those public issues in society, which has added a huge burden to both the individuals and the society. In the current clinical stage, there are numerous drugs developed to treat this disease, and different drug treatment measures have been proven to achieve certain clinical efficacy in the corresponding randomized controlled trials. However, there are still many therapeutic drugs that have not been directly compared and studied. Therefore, it is difficult to directly compare the effectiveness and safety of various strategies for the treatment of DILI. In this regard, the present study collected the therapeutic efficacy of diverse treatments in DILI in recent years through network meta-analysis, evaluated and screened the existing optimal clinical therapeutic plan, and helped physicians formulate clinical therapeutic plans. Methods: Databases, including the Chinese Journal Full-text Database, Wanfang Data Journal Paper Resources (Wangfang), VIP Chinese Science and Technology Journal Full-text Database, The Cochrane Library, PubMed, and EMBASE, were searched using keywords from inception to January 2023. Eligible randomized controlled trials were selected in line with eligibility criteria, and mesh meta-analysis of binary variables was carried out using Stata 16 software. Conclusion: In combination with alanine aminotransferase, aspartate aminotransferase, and total bilirubin, MI may be the intervention measure for minimizing alanine aminotransferase levels in patients after treatment. Besides, compound glycyrrhizin may be the intervention for minimizing aspartate aminotransferase levels in patients after treatment, and polyene phosphatidylcholine may be the intervention for minimizing total bilirubin levels in patients after treatment. Placebo is the potential intervention that has the least adverse reactions post-treatment, and RT has the second least adverse reactions. Moreover, hepatocyte growth-promoting factors may be the most effective intervention after treatment. Results: To sum up, the present work compared the clinical effects of 13 liver protective drugs through meta-analysis and provided a systematic understanding of commonly used drugs for the treatment of DILI in clinical practice.
MnO2 Coated Mesoporous PdPt Nanoprobes for Scavenging Reactive Oxygen Species and Solving Acetaminophen‐induced Liver Injury

Yi Lu,Xinni Pan,Cheng Cao,Shanshan Fan,Haisong Tan,Shengsheng Cui,Yanlei Liu,Daxiang Cui

DOI: https://doi.org/10.1002/adhm.202300163

IF: 10

2023-05-17

Advanced Healthcare Materials

Abstract:As one of the most widely used drugs, acetaminophen, is the leading cause of acute liver injury. In addition, Acetaminophen‐induced liver injury (AILI) has a strong relationship with the overproduced reactive oxygen species, which can be effectively eliminated by nanozymes. To address these challenges, we synthesized mesoporous PdPt@MnO2 nanoprobes (PPM NPs) mimicking peroxide, catalase, and superoxide dismutase‐like properties. They demonstrated nontoxicity, high colloidal stability, and exceptional ROS‐scavenging ability. By scavenging excessive ROS, decreasing inflammatory cytokines, and inhibiting the recruitment and activation of monocyte/macrophage cells and neutrophils, the pathology mechanism of PPM NPs in AILI was confirmed. Moreover, PPM NPs' therapeutic effect and good biocompatibility may facilitate the clinical treatment of AILI. This article is protected by copyright. All rights reserved

nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials
Evaluation of the hepatoprotective effect of naringenin loaded nanoparticles against acetaminophen overdose toxicity

Ruijie Lu,Run-Jie Yu,Chunhui Yang,Qian Wang,Yunxia Xuan,Zeqing Wang,Zhimin He,Yan Xu,Longfa Kou,Ying-Zheng Zhao,Qing Yao,Shi-Hao Xu

DOI: https://doi.org/10.1080/10717544.2022.2139431

IF: 6.819

2022-11-04

Drug Delivery

Abstract:Acute liver injury is a common clinical disease, which easily leads to liver failure and endangers life, seriously threatening human health. Naringenin is a natural flavonoid that holds therapeutic potential against various liver injuries; however it has poor water solubility and bioavailability. In this study, we aimed to develop naringenin-loaded bovine serum albumin nanoparticles (NGNPs) and to evaluate their hepatoprotective effect and underlying mechanisms against acetaminophen overdose toxicity. In vitro data indicated that NGNPs significantly increased the drug solubility and also more effectively protected the hepatocyte cells from oxidative damage during hydrogen peroxide exposure or lipopolysaccharide (LPS) stimulation. In vivo results confirmed that NGNPs showed an enhanced accumulation in the liver tissue. In the murine model of acetaminophen-induced hepatotoxicity, NGNPs could effectively alleviate the progression of acute liver injury by reducing drug overdose-induced levels of oxidative stress, inflammation and apoptosis in hepatocytes. In conclusion, NGNPs has strong hepatoprotective effects against acetaminophen induced acute liver injury.

pharmacology & pharmacy
Progress in the treatment of drug-induced liver injury with natural products

Yuan-Kai Sun,Ya-Fei Zhang,Li Xie,Fan Rong,Xing-Yu Zhu,Jing Xie,Huan Zhou,Tao Xu,Yuan-kai Sun,Ya-fei Zhang,Xing-yu Zhu

DOI: https://doi.org/10.1016/j.phrs.2022.106361

IF: 10.334

2022-09-01

Pharmacological Research

Abstract:There are numerous prescription drugs and non-prescription drugs that cause drug-induced liver injury (DILI), which is the main cause of liver disease in humans around the globe. Its mechanism becomes clearer as the disease is studied further. For an instance, when acetaminophen (APAP) is taken in excess, it produces N-acetyl-p-benzoquinone imine (NAPQI) that binds to biomacromolecules in the liver causing liver injury. Treatment of DILI with traditional Chinese medicine (TCM) has shown to be effective. For example, activation of the Nrf2 signaling pathway as well as regulation of glutathione (GSH) synthesis, coupling, and excretion are the mechanisms by which ginsenoside Rg1 (Rg1) treats APAP-induced acute liver injury. Nevertheless, reducing the toxicity of TCM in treating DILI is still a problem to be overcome at present and in the future. Accumulated evidences show that hydrogel-based nanocomposite may be an excellent carrier for TCM. Therefore, we reviewed TCM with potential anti-DILI, focusing on the signaling pathway of these drugs' anti-DILI effect, as well as the possibility and prospect of treating DILI by TCM based on hydrogel materials in the future. In conclusion, this review provides new insights to further explore TCM in the treatment of DILI.

pharmacology & pharmacy
Bile acid-based polydrug nanoparticles for the treatment of acute liver injury

Hanui Jo,Lipjung Jung,Nuri Kim,Gi-Wook Kim,Dongwon Lee

DOI: https://doi.org/10.1007/s13233-023-00241-7

IF: 2.127

2024-02-14

Macromolecular Research

Abstract:Acute liver failure and non-alcoholic fatty liver disease (NAFLD) are a common chronic liver disease worldwide, causing tremendous clinical burden. Despite the increasing prevalence of these life-threatening liver damages, effective medical treatment has not been established. Here, we developed a new treatment strategy based on ursodeoxycholic acid (UDCA) which is one of bile acids and effective for the liver diseases. We designed poly(ursodeoxycholic acid-oxalate) (PUOX) as a polymer prodrug of UDCA. PUOX has hydrogen peroxide (H 2 O 2 )-scavenging peroxalate ester bonds and could be formulated into nanoparticles. PUOX nanoparticles released UDCA in a H 2 O 2 -triggered manner and exerted concurrent antioxidant and anti-inflammatory effects with cytoprotective actions. In mouse models of acute liver failure and NAFLD, PUOX nanoparticles exerted highly potent therapeutic effects without noticeable toxicity. PUOX nanoparticles could be a promising approach to improve the efficacy for various H 2 O 2 -associated liver disease.

polymer science
NIR-excited imaging of drug-induced liver injury using a superoxide-activated ratiometric upconversion luminescence nanoprobe

Yuhan Shen,Yuhang Zhu,Zhenghao Xiao,Qin Zhang,Yuanjun Li,Chengkang Li,Minan Ye,Chenjie Zhu,Yi Zhou

DOI: https://doi.org/10.1016/j.talanta.2024.126599

IF: 6.1

2024-11-01

Talanta

Abstract:Drug-induced liver injury (DILI) poses a significant risk to human health. Increasing evidence indicates that the superoxide anion (O2•-), as the precursor of the other reactive oxygen species, is key in the pathological processes associated with DILI. Nonetheless, understanding of the mechanisms of DILI is difficult due to the lack of an imaging tool for monitoring the fluctuation of O2•- levels during the progression of DILI. Herein, we developed an upconversion nanoprobe (Rbh-UCNs) for in vivo ratiometric tracking of endogenous O2•- in DILI. In this design, the addition of O2•- triggers the luminescent resonance energy transfer between Rbh and UCNs, which significantly enhances absorption centered at 534 nm and translates into a distinct decrease of the UCL emission at 543 nm, while the UCL emission peak at 654 nm and 800 nm are not significantly affected, offering a ratiometric UCL signal for the quantitative detection of O2•-. In addition, Rbh-UCNs could effectively visualize endogenous O2•- in living cells, zebrafish, and liver tissues upon stimulation with PMA or cisplatin. More importantly, tissue imaging of the liver region of mice revealed that the fluctuation of O2•- levels is associated with DILI and the protective effect of L-carnitine against DILI. Altogether, this study provides an available method for a deeper comprehension of the mechanisms underlying DILI and accelerating the development process of hepatoprotective medicines.
Reactive Oxygen Species Scavenging Nanozymes: Emerging Therapeutics for Acute Liver Injury Alleviation

Tao Sun,Shilin Xiao,Miaomiao Wang,Qian Xie,Liang Zhang,Mingfu Gong,Dong Zhang,Chunyu Zhou

DOI: https://doi.org/10.2147/ijn.s435544

IF: 7.033

2023-01-01

International Journal of Nanomedicine

Abstract:Acute liver injury (AIL), a fatal clinical disease featured with a swift deterioration of hepatocyte functions in the short term, has emerged as a serious public health issues that warrants attention. However, the effectiveness of existing small molecular antioxidants and anti-inflammatory medications in alleviating AIL remains uncertain. The unique inherent structural characteristics of liver confer it a natural propensity for nanoparticle capture, which present an opportunity to exploit in the formulation of nanoscale therapeutic agents, enabling their selective accumulation in the liver and thereby facilitating targeted therapeutic interventions. Significantly increased reactive oxygen species (ROS) accumulation and inflammation response have been evidenced to play crucial roles in occurrence and development of AIL. Nanozymes with ROS-scavenging capacities have demonstrated considerable promise in ROS elimination and inflammation regulation, thereby offering an appealing therapeutic instrument for the management of acute liver injury. In this review, the mechanisms of different type of ALI were summarized. In addition, we provide a comprehensive summary and review of the available ROS-scavenging nanozymes, including transition metal-based nanozymes, noble metal nanozymes, carbon-based nanozymes, and some other nanozymes. Furthermore, the challenges still need to be solved in the field of ROS-scavenging nanozymes for ALI alleviation are also discussed.
Innate immune regulation in inflammation resolution and liver regeneration in drug-induced liver injury

Yihan Qian,Jie Zhao,Hailong Wu,Xiaoni Kong

DOI: https://doi.org/10.1007/s00204-024-03886-0

2024-10-13

Archives of Toxicology

Abstract:Drug-induced liver injury (DILI) is an acute liver injury that poses a significant threat to human health. In severe cases, it can progress into chronic DILI or even lead to liver failure. DILI is typically caused by either intrinsic hepatotoxicity or idiosyncratic metabolic or immune responses. In addition to the direct damage drugs inflict on hepatocytes, the immune responses and liver inflammation triggered by hepatocyte death can further exacerbate DILI. Initially, we briefly discussed the differences in immune cell activation based on the type of liver cell death (hepatocytes, cholangiocytes, and LSECs). We then focused on the role of various immune cells (including macrophages, monocytes, neutrophils, dendritic cells, liver sinusoidal endothelial cells, eosinophils, natural killer cells, and natural killer T cells) in both the liver injury and liver regeneration stages of DILI. This article primarily reviews the role of innate immune regulation mediated by these immune cells in resolving inflammation and promoting liver regeneration during DILI, as well as therapeutic approaches targeting these immune cells for the treatment of DILI. Finally, we discussed the activation and function of liver progenitor cells (LPCs) during APAP-induced massive hepatic necrosis and the involvement of chronic inflammation in DILI.

toxicology
Prevention of Hepatic Ischemia-Reperfusion Injury by Carbohydrate-Derived Nanoantioxidants

Yin Long,Hao Wei,Jun Li,Mengting Li,Yizhan Wang,Ziyi Zhang,Tianye Cao,Corey Carlos,Lazarus G. German,Dawei Jiang,Tuanwei Sun,Jonathan W. Engle,Xiaoli Lan,Yadong Jiang,Weibo Cai,Xudong Wang

DOI: https://doi.org/10.1021/acs.nanolett.0c02248

IF: 10.8

2020-08-12

Nano Letters

Abstract:Hepatic ischemia-reperfusion injury (IRI), which mainly results from excessive reactive oxygen species (ROS) generated by a reperfusion burst of oxygen, has long been a major cause of liver dysfunction and failure after surgical procedures. Here, a monodispersed hydrophilic carbohydrate-derived nanoparticle (C-NP) was synthesized as a nanoantioxidant that could effectively prevent hepatic IRI. The spherical C-NPs had a size of ∼78 ± 11.3 nm covered with polar surface groups. They were well dispersible in water with good colloidal stability, nontoxicity, and good ROS scavenging capability. The C-NPs also exhibited good circulation lifetime, effective delivery to liver, and gradual degradability with an ability to assist the IRI group maintaining a normal and healthy liver status. The pathology mechanism of C-NPs in hepatic IRI was confirmed to be scavenging of excessive ROS by C-NPs. The effective therapeutic treatment of C-NPs in living animals revealed a great potential in clinical prevention for hepatic IRI.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.nanolett.0c02248?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.nanolett.0c02248</a>.Experimental details; AFM images, XPS spectra, and UV–vis absorbance of C-NPs; optical image, XPS spectra and SEM characterizations of C-NP reaction with H2O2; in vitro cell viabilities and time-dependent cellular uptake of C-NPs; autoradiography of TLC plates; 89Zr labeling yields PET images of mice i.v. injected with 89Zr–C–NPs and free Zr-89; cytotoxicity evaluation on liver; long-term cytotoxicity on blood serum; H&E-stained images from major organs; Suzuki Score of liver (<a class="ext-link" href="/doi/suppl/10.1021/acs.nanolett.0c02248/suppl_file/nl0c02248_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
Self-Propelled Ultrasmall AuNPs-Tannic Acid Hybrid Nanozyme with ROS-Scavenging and Anti-Inflammatory Activity for Drug-Induced Liver Injury Alleviation.

Chunyu Zhou,Liang Zhang,Zhongsheng Xu,Tao Sun,Mingfu Gong,Yun Liu,Dong Zhang

DOI: https://doi.org/10.1002/smll.202206408

IF: 13.3

2023-01-01

Small

Abstract:Developing nanomedicines with superior reactive oxygen species (ROS) scavenging capability has emerged as a promising strategy in treating ROS-related diseases, for example, drug-induced liver injury. However, designing nanoscavengers with the self-propelling ability to scavenge ROS actively remains challenging. Here, a self-propelled silica-supported ultrasmall gold nanoparticles-tannic acid hybrid nanozyme (SAuPTB) is designed that can effectively alleviate acetaminophen (APAP)-induced liver injury by scavenging excessive ROS and regulating inflammation. SAuPTB exhibits multienzyme activity and displays significantly enhanced diffusion under hydrogen peroxide (H2O2). This in vitro research shows that SAuPTB can effectively eliminate ROS, increasing the viability of H2O2-stimulated cells and reducing the cytotoxicity of APAP/H2O2-treated AML12 cells. The in vivo studies show that SAuPTB can accumulate at inflammatory sites in mouse liver, resulting in the decrease of alanine aminotransferase, aspartate aminotransferase, and ROS, reduction in pro-inflammatory cytokines and chemokines, hence reduced hepatocyte necrosis, liver injury, and mortality. Furthermore, SAuPTB activates the nuclear erythroid 2-related factor 2 pathway to upregulate antioxidative genes and reduce oxidative stress. Finally, the liver shows decreased high mobility group box 1 and F4/80(+) macrophages, suggesting an anti-inflammatory response. This work provides a novel design strategy of nanozymes for ROS-related disease treatment.
Therapeutic Potential of Nutraceuticals against Drug-Induced Liver Injury

Namya Sethi,Manoj Khokhar,Mitali Mathur,Yashi Batra,Amal Mohandas,Sojit Tomo,Mahadev Rao,Mithu Banerjee

DOI: https://doi.org/10.1055/s-0044-1791559

2024-10-13

Seminars in Liver Disease

Abstract:Drug-induced liver injury (DILI) continues to be a major concern in clinical practice, thus necessitating a need for novel therapeutic approaches to alleviate its impact on hepatic function. This review investigates the therapeutic potential of nutraceuticals against DILI, focusing on examining the underlying molecular mechanisms and cellular pathways. In preclinical and clinical studies, nutraceuticals, such as silymarin, curcumin, and N-acetylcysteine, have demonstrated remarkable efficacy in attenuating liver injury induced by diverse pharmaceutical agents. The molecular mechanisms underlying these hepatoprotective effects involve modulation of oxidative stress, inflammation, and apoptotic pathways. Furthermore, this review examines cellular routes affected by these nutritional components focusing on their influence on hepatocytes, Kupffer cells, and stellate cells. Key evidence highlights that autophagy modulation as well as unfolded protein response are essential cellular processes through which nutraceuticals exert their cytoprotective functions. In conclusion, nutraceuticals are emerging as promising therapeutic agents for mitigating DILI, by targeting different molecular pathways along with cell processes involved in it concurrently. N.S. conceptualized and wrote the manuscript. M.K. edited the manuscript and prepared the figures and tables. M.M. wrote and edited the manuscript. Y.B. wrote and edited the manuscript. A.M. edited the manuscript. S.T. edited the manuscript. M.R. edited the manuscript. M.B. conceptualized, wrote, and edited the manuscript. Article published online: 11 October 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

gastroenterology & hepatology
Prevention of Hepatic Ischemia-Reperfusion Injury by Carbohydrate-derived Nano-antioxidants.

Yin Long,Hao Wei,Jun Li,Mengting Li,Yizhan Wang,Ziyi Zhang,Tianye Cao,Corey Carlos,Lazarus G German,Dawei Jiang,Tuanwei Sun,Jonathan W Engle,Xiaoli Lan,Yadong Jiang,Weibo Cai,Xudong Wang

DOI: https://doi.org/10.1021/acs.nanolett.0c02248

IF: 10.8

2020-01-01

Nano Letters

Abstract:Hepatic ischemia-reperfusion injury (IRI), which mainly results from excessive reactive oxygen species (ROS) generated by a reperfusion burst of oxygen, has long been a major cause of liver dysfunction and failure after surgical procedures. Here, a monodispersed hydrophilic carbohydrate-derived nanoparticle (C-NP) was synthesized as a nanoantioxidant that could effectively prevent hepatic IRI. The spherical C-NPs had a size of similar to 78 +/- 11.3 nm covered with polar surface groups. They were well dispersible in water with good colloidal stability, nontoxicity, and good ROS scavenging capability. The C-NPs also exhibited good circulation lifetime, effective delivery to liver, and gradual degradability with an ability to assist the IRI group maintaining a normal and healthy liver status. The pathology mechanism of C-NPs in hepatic IRI was confirmed to be scavenging of excessive ROS by C-NPs. The effective therapeutic treatment of C-NPs in living animals revealed a great potential in clinical prevention for hepatic IRI.
Megalin-targeted acetylcysteine polymeric prodrug ameliorates ischemia-reperfusion-induced acute kidney injury

Hao-Le Huang,Na Cheng,Can-Xin Zhou,Jing Liang

DOI: https://doi.org/10.1016/j.heliyon.2024.e30947

IF: 3.776

2024-05-09

Heliyon

Abstract:Acute kidney injury (AKI), a condition associated with reactive oxygen species (ROS), causes high mortality in clinics annually. Active targeted antioxidative therapy is emerging as a novel strategy for AKI treatment. In this study, we developed a polymeric prodrug that targets the highly expressed Megalin receptor on proximal tubule cells, enabling direct delivery of N-Acetylcysteine (NAC) for the treatment of ischemia reperfusion injury (IRI)-induced AKI. We conjugated NAC with low molecular weight chitosan (LMWC), a biocompatible and biodegradable polymer consisting of glucosamine and N-acetylglucosamine, to enhance its internalization by tubular epithelial cells. Moreover, we further conjugated triphenylphosphonium (TPP), a lipophilic cation with a delocalized positive charge, to low molecular weight chitosan-NAC in order to enhance the distribution of NAC in mitochondria. Our study confirmed that triphenylphosphonium-low molecular weight chitosan-NAC (TLN) exhibits remarkable therapeutic effects on IRI-AKI mice. This was evidenced by improvements in renal function, reduction in oxidative stress, mitigation of pathological progress, and decreased levels of kidney injury molecule-1. These findings suggested that the polymeric prodrug TLN holds promising potential for IRI-AKI treatment.

Brief communication: Effect of chlorambucil on thymidine utilization by Yoshida ascites tumor cells.

Single-cell RNA Sequencing Reveals the Dynamics of Hepatic Non-Parenchymal Cells in Autoprotection Against Acetaminophen-Induced Hepatotoxicity

Epigallocatechin-3-gallate Mo nanoparticles (EGM NPs) efficiently treat liver injury by strongly reducing oxidative stress, inflammation and endoplasmic reticulum stress

Multienzyme Active Manganese Oxide Alleviates Acute Liver Injury by Mimicking Redox Regulatory System and Inhibiting Ferroptosis

Preclinical Validation of Silibinin/albumin Nanoparticles As an Applicable System Against Acute Liver Injury.

Alteration of Bile Acids and Omega-6 PUFAs Are Correlated With the Progression and Prognosis of Drug-Induced Liver Injury

Bifidobacterium Longum R0175 Protects Mice Against APAP-induced Liver Injury by Modulating the Nrf2 Pathway.

Dual detoxification and inflammatory regulation by ceria nanozymes for drug-induced liver injury therapy

Network meta-analysis of different liver protective drugs in the treatment of drug-induced liver injury

MnO2 Coated Mesoporous PdPt Nanoprobes for Scavenging Reactive Oxygen Species and Solving Acetaminophen‐induced Liver Injury

Evaluation of the hepatoprotective effect of naringenin loaded nanoparticles against acetaminophen overdose toxicity

Progress in the treatment of drug-induced liver injury with natural products

Bile acid-based polydrug nanoparticles for the treatment of acute liver injury

NIR-excited imaging of drug-induced liver injury using a superoxide-activated ratiometric upconversion luminescence nanoprobe

Reactive Oxygen Species Scavenging Nanozymes: Emerging Therapeutics for Acute Liver Injury Alleviation

Innate immune regulation in inflammation resolution and liver regeneration in drug-induced liver injury

Prevention of Hepatic Ischemia-Reperfusion Injury by Carbohydrate-Derived Nanoantioxidants

Self-Propelled Ultrasmall AuNPs-Tannic Acid Hybrid Nanozyme with ROS-Scavenging and Anti-Inflammatory Activity for Drug-Induced Liver Injury Alleviation.

Therapeutic Potential of Nutraceuticals against Drug-Induced Liver Injury

Prevention of Hepatic Ischemia-Reperfusion Injury by Carbohydrate-derived Nano-antioxidants.

Megalin-targeted acetylcysteine polymeric prodrug ameliorates ischemia-reperfusion-induced acute kidney injury